Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 203,185Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 1Onbrez Breezhaler

02 5Onbrez Breezhaler/Arcapta Neohaler

03 5Ultibro Breezhaler

04 2Ultibro Group

PharmaCompass

01

Brand Name : Ultibro Group

Indacaterol

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Ultibro Group

arrow
2024 ACI Convention
Not Confirmed

Indacaterol

Main Therapeutic Indication : Respiratory Disorders

Currency : USD

2020 Revenue in Millions : 623

2019 Revenue in Millions : 630

Growth (%) : -1

blank

02

Brand Name : Ultibro Group

Indacaterol

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Ultibro Group

arrow
2024 ACI Convention
Not Confirmed

Indacaterol

Main Therapeutic Indication : Respiratory Diseases

Currency : USD

2022 Revenue in Millions : 479

2021 Revenue in Millions : 584

Growth (%) : -18

blank

03

Brand Name : Onbrez Breezhaler

Indacaterol Maleate

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Onbrez Breezhaler

arrow
2024 ACI Convention
Not Confirmed

Indacaterol Maleate

Main Therapeutic Indication : Respiratory Disorders

Currency : USD

2014 Revenue in Millions : 14.60%

2013 Revenue in Millions :

Growth (%) :

blank

04

Brand Name : Ultibro Breezhaler

Indacaterol / Glycopyrronium Bromide

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Ultibro Breezhaler

arrow
2024 ACI Convention
Not Confirmed

Indacaterol / Glycopyrronium Bromide

Main Therapeutic Indication : Respiratory Disorders

Currency : USD

2014 Revenue in Millions : 1866.70%

2013 Revenue in Millions :

Growth (%) :

blank

05

Brand Name : Onbrez Breezhaler/Arcapta Neohaler

Indacaterol Maleate

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Onbrez Breezhaler/Arcapta Neohaler

arrow
2024 ACI Convention
Not Confirmed

Indacaterol Maleate

Main Therapeutic Indication : Respiratory Disorders

Currency : USD

2015 Revenue in Millions : 220

2014 Revenue in Millions : 166

Growth (%) : -25%

blank

06

Brand Name : Ultibro Breezhaler

Indacaterol And Glycopyrronium Bromide

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Ultibro Breezhaler

arrow
2024 ACI Convention
Not Confirmed

Indacaterol And Glycopyrronium Bromide

Main Therapeutic Indication : Respiratory Disorders

Currency : USD

2016 Revenue in Millions : 363

2015 Revenue in Millions : 260

Growth (%) : 40

blank

07

Brand Name : Onbrez Breezhaler/Arcapta Neohaler

Indacaterol Maleate

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Onbrez Breezhaler/Arcapta Neohaler

arrow
2024 ACI Convention
Not Confirmed

Indacaterol Maleate

Main Therapeutic Indication : Respiratory Disorders

Currency : USD

2016 Revenue in Millions : 143

2015 Revenue in Millions : 166

Growth (%) : -14

blank

08

Brand Name : Ultibro Breezhaler

Indacaterol and Glycopyrronium Bromide

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Ultibro Breezhaler

arrow
2024 ACI Convention
Not Confirmed

Indacaterol and Glycopyrronium Bromide

Main Therapeutic Indication : Respiratory Disorders

Currency : USD

2017 Revenue in Millions : 411

2016 Revenue in Millions : 363

Growth (%) : 13

blank

09

Brand Name : Onbrez Breezhaler/Arcapta Neohaler

Indacaterol Maleate

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Onbrez Breezhaler/Arcapta Neohaler

arrow
2024 ACI Convention
Not Confirmed

Indacaterol Maleate

Main Therapeutic Indication : Respiratory Disorders

Currency : USD

2017 Revenue in Millions : 112

2016 Revenue in Millions : 143

Growth (%) : -22

blank

10

Brand Name : Ultibro Breezhaler

Indacaterol And Glycopyrronium Bromide

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Ultibro Breezhaler

arrow
2024 ACI Convention
Not Confirmed

Indacaterol And Glycopyrronium Bromide

Main Therapeutic Indication : Respiratory Disorders

Currency : USD

2018 Revenue in Millions : 454

2017 Revenue in Millions : 411

Growth (%) : 10%

blank